These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 23295698)

  • 1. Topical therapy.
    Gross V
    Dig Dis; 2012; 30 Suppl 3():92-9. PubMed ID: 23295698
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A practical guide to the management of distal ulcerative colitis.
    Ardizzone S; Bianchi Porro G
    Drugs; 1998 Apr; 55(4):519-42. PubMed ID: 9561342
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mesalazine foam (Salofalk foam) in the treatment of active distal ulcerative colitis. A comparative trial vs Salofalk enema. The SAF-3 study group.
    Ardizzone S; Doldo P; Ranzi T; Sturniolo GC; Giglio LA; Annese V; D'Arienzo A; Gaia E; Gullini S; Riegler G; Valentini M; Massa P; Del Piano M; Rossini F; Guidetti CS; Pera A; Greinwald R; Bianchi Porro G
    Ital J Gastroenterol Hepatol; 1999 Nov; 31(8):677-84. PubMed ID: 10730559
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical trial: controlled, open, randomized multicentre study comparing the effects of treatment on quality of life, safety and efficacy of budesonide or mesalazine enemas in active left-sided ulcerative colitis.
    Hartmann F; Stein J;
    Aliment Pharmacol Ther; 2010 Aug; 32(3):368-76. PubMed ID: 20491741
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Budesonide foam as a new therapeutic principle in distal ulcerative colitis in comparison with mesalazine enema. An open, controlled, randomized and prospective multicenter pilot study].
    Rufle W; Frühmorgen P; Huber W; Kimmig JM
    Z Gastroenterol; 2000 Apr; 38(4):287-93. PubMed ID: 10820860
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Early symptomatic response and mucosal healing with mesalazine rectal suspension therapy in active distal ulcerative colitis--additional results from two controlled studies.
    Sandborn WJ; Hanauer S; Lichtenstein GR; Safdi M; Edeline M; Scott Harris M
    Aliment Pharmacol Ther; 2011 Oct; 34(7):747-56. PubMed ID: 21848857
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of prolonged release budesonide granules in mesalazine-refractory ulcerative colitis: A multi-centre Phase IIa study (TOPICAL-1).
    Fellermann K; Schiefke I; Rácz I; Derova J; Jonaitis L; Wehrum S; Nacak T; Greinwald R
    United European Gastroenterol J; 2020 Dec; 8(10):1186-1195. PubMed ID: 33028169
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Review article: delivery and efficacy of topical 5-aminosalicylic acid (mesalazine) therapy in the treatment of ulcerative colitis.
    Harris MS; Lichtenstein GR
    Aliment Pharmacol Ther; 2011 May; 33(9):996-1009. PubMed ID: 21385194
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Putting rectal 5-aminosalicylic acid in its place: the role in distal ulcerative colitis.
    Marshall JK; Irvine EJ
    Am J Gastroenterol; 2000 Jul; 95(7):1628-36. PubMed ID: 10925961
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Topical therapy is underused in patients with ulcerative colitis.
    Seibold F; Fournier N; Beglinger C; Mottet C; Pittet V; Rogler G;
    J Crohns Colitis; 2014 Jan; 8(1):56-63. PubMed ID: 23566922
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Factors associated with early outcomes following standardised therapy in children with ulcerative colitis (PROTECT): a multicentre inception cohort study.
    Hyams JS; Davis S; Mack DR; Boyle B; Griffiths AM; LeLeiko NS; Sauer CG; Keljo DJ; Markowitz J; Baker SS; Rosh J; Baldassano RN; Patel A; Pfefferkorn M; Otley A; Heyman M; Noe J; Oliva-Hemker M; Rufo P; Strople J; Ziring D; Guthery SL; Sudel B; Benkov K; Wali P; Moulton D; Evans J; Kappelman MD; Marquis A; Sylvester FA; Collins MH; Venkateswaran S; Dubinsky M; Tangpricha V; Spada KL; Britt A; Saul B; Gotman N; Wang J; Serrano J; Kugathasan S; Walters T; Denson LA
    Lancet Gastroenterol Hepatol; 2017 Dec; 2(12):855-868. PubMed ID: 28939374
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Topical therapy of ulcerative colitis].
    Rogler G; Beglinger C; Mottet C; Seibold F; Gross V
    Praxis (Bern 1994); 2011 Nov; 100(23):1413-24. PubMed ID: 22086380
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Once daily MMX mesalazine for the treatment of mild-to-moderate ulcerative colitis: a phase II, dose-ranging study.
    D'Haens G; Hommes D; Engels L; Baert F; van der Waaij L; Connor P; Ramage J; Dewit O; Palmen M; Stephenson D; Joseph R
    Aliment Pharmacol Ther; 2006 Oct; 24(7):1087-97. PubMed ID: 16984503
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Quality of life improvements attributed to combination therapy with oral and topical mesalazine in mild-to-moderately active ulcerative colitis.
    Connolly MP; Poole CD; Currie CJ; Marteau P; Nielsen SK
    Digestion; 2009; 80(4):241-6. PubMed ID: 19828955
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combined oral and topical mesalazine treatment for extensive ulcerative colitis.
    Moss AC; Cheifetz AS; Peppercorn MA
    Nat Clin Pract Gastroenterol Hepatol; 2006 May; 3(5):290-3. PubMed ID: 16673009
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Topical therapies in inflammatory bowel disease.
    Frei P; Biedermann L; Manser CN; Wilk M; Manz M; Vavricka SR; Rogler G
    Digestion; 2012; 86 Suppl 1():36-44. PubMed ID: 23051725
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Beclomethasone dipropionate versus mesalazine in distal ulcerative colitis: a multicenter, randomized, double-blind study.
    Biancone L; Gionchetti P; Blanco Gdel V; Orlando A; Annese V; Papi C; Sostegni R; D'Incà R; Petruzziello C; Casa A; Sica G; Calabrese E; Campieri M; Pallone F
    Dig Liver Dis; 2007 Apr; 39(4):329-37. PubMed ID: 17347061
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Local or systemic treatment of inflammatory bowel diseases?].
    Schmassmann A; Halter F
    Ther Umsch; 1993 Feb; 50(2):94-9. PubMed ID: 8096092
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical trial: randomized-controlled clinical study comparing the efficacy and safety of a low-volume vs. a high-volume mesalazine foam in active distal ulcerative colitis.
    Eliakim R; Tulassay Z; Kupcinskas L; Adamonis K; Pokrotnieks J; Bar-Meir S; Lavy A; Mueller R; Greinwald R; Chermesh I; Gross V;
    Aliment Pharmacol Ther; 2007 Nov; 26(9):1237-49. PubMed ID: 17944738
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Low-dose balsalazide plus a high-potency probiotic preparation is more effective than balsalazide alone or mesalazine in the treatment of acute mild-to-moderate ulcerative colitis.
    Tursi A; Brandimarte G; Giorgetti GM; Forti G; Modeo ME; Gigliobianco A
    Med Sci Monit; 2004 Nov; 10(11):PI126-31. PubMed ID: 15507864
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.